Grapevine Leafroll Virus (GLRaV-3) and trunk disease don't just reduce yield — they reduce future vineyard value. BARS converts biological condition into financial intelligence: quantifying the cost of inaction, the return on intervention, and which blocks carry the greatest share of that risk.
GLRaV-3 and trunk disease don't announce themselves on a P&L. They show up as slightly lower yield, a slightly earlier replant, a vector count that's crept up — spread across dozens of blocks, unnoticed until the cost is too large to reverse. BARS Institute puts a number on that hidden cost, block by block, and shows which response — tighter vector control, closer monitoring, or replanting — actually pays for itself.
Financial outputs
Four outputs that PCR testing alone cannot produce — built on accredited diagnostics, epidemiological modelling, and discounted cashflow analysis.
Disease-driven revenue loss and replant CAPEX, expressed per hectare and as a percentage of clean vineyard value. Reported as median (P50) and stress-case (P95) outcomes, virus and trunk disease separately.
Compares intervention scenarios — tighter vector management, intensified monitoring, targeted vine removal — to quantify whether additional operational effort on a given block actually pays for itself.
Ranks blocks by their contribution to total portfolio biological risk. Shows which blocks are driving the downside — and where intervention has the greatest financial return.
Projects when each block will reach its economic replant threshold, based on current disease burden, trunk disease progression rate, and productive life remaining.
Supporting scientific metrics
GLRaV-3 infection prevalence, expressed as a current-condition score from 0–100. Derived from ISO/IEC 17025 accredited PCR results using validated composite pool testing.
Current trunk disease burden expressed as a score from 0–100, assessed across three tiers. Each figure carries a tier confidence label and disclosed uncertainty interval.
Expertise and standards
Large-scale vineyard operators already have experienced technical teams who know their blocks. BARS doesn't replace that judgement — it provides the independent, standardised layer that converts what your team observes into a comparable dollar figure across every block, every region, and every season. The same evidence also supports lenders, valuers, accountants, and transaction advisers where a transaction, covenant review, or audit requires independent evidence.
Sarah Macfarlane is a former IANZ-accredited Key Technical Person for plant virus detection within an ISO/IEC 17025 laboratory. She has led commercial grapevine virus testing programmes, developed diagnostic quality systems, and managed vineyard-scale health surveillance across New Zealand. BARS Institute translates that technical depth into a standardised, independent risk and capital model for vineyard operators.
All assessments follow published methodology MET-BARS-001, with assumptions, calibration bases, and sensitivity ranges disclosed in every report. Diagnostic samples are submitted to independent IANZ-accredited laboratories under full chain-of-custody documentation.
Outputs are designed for direct use in impairment testing, fair value assessment, and due diligence workflows aligned with these standards.
Contact Sarah Macfarlane directly to discuss where hidden biological cost might be concentrated across your blocks.
Get in touch →BARS outputs are decision-support evidence, not a registered valuation, accounting opinion, or credit approval recommendation. They do not determine market value, loan terms, impairment recognition, or financial statement treatment.